Granted Patent
B2
US 12,583,903 · App. 17/831,637 · Granted Mar 24, 2026
Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof
Inventors:
Yihong Yao (Rockville, MD); Jiaqi Huang (Rockville, MD); Shigui Zhu (Rockville, MD); Wei Zhu (Rockville, MD); Xin Yao (Rockville, MD); Zhiyuan Li (Hong Kong, CN); Li Zhang (Rockville, MD); Lin Zhu (Hong Kong, CN); Anyun Ma (Hong Kong, CN); Yutian Wei (Hong Kong, CN); Yanfeng Li (Hong Kong, CN); Qingxia Wang (Hong Kong, CN); Jiaping He (Hong Kong, CN)
Assignee:
AbelZeta Inc.
C07K14/7051A61K9/0019A61K40/11A61K40/31A61K40/4221A61P35/00A61P35/02C07K14/70517C07K14/70521C07K14/70578C07K16/2887C07K19/00C12N5/0636C12N5/10C12N7/00C12N15/62C12N15/86A61K38/00A61K2039/505A61K2039/54C07K2317/524C07K2317/526C07K2317/53C07K2317/622C07K2317/732C07K2317/76C07K2319/02C07K2319/03C07K2319/30C07K2319/33C12N2740/15043C12N2750/14143
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Provided are a chimeric antigen receptor targeting CD20 antigen and a preparation method thereof. The extracellular antigen binding domain of the chimeric antigen receptor includes an antibody heavy chain variable region shown in SEQ ID NO: 7 or 9 or 33 and an antibody light chain variable region shown in SEQ ID NO: 11 or 13 or 35, and is capable of killing tumor cells.
Claims (10)
1 . A nucleic acid encoding a chimeric antigen receptor (CAR), wherein the CAR comprises an amino acid sequence set forth in SEQ ID NO: 5.
2 . A vector comprising a nucleic acid which encodes a chimeric antigen receptor (CAR), wherein the CAR comprises an amino acid sequence set forth in SEQ ID NO: 5.
3 . A pharmaceutical composition comprising a vector, wherein the vector comprises a nucleic acid encoding a chimeric antigen receptor (CAR), and wherein the CAR comprises an amino acid sequence set forth in SEQ ID NO: 5.
4 . An immune cell comprising a nucleic acid which encodes a chimeric antigen receptor (CAR), wherein the CAR comprises an amino acid sequence set forth in SEQ ID NO: 5.
5 . A pharmaceutical composition comprising an immune cell, wherein the immune cell comprises a nucleic acid encoding a chimeric antigen receptor (CAR), and wherein the CAR comprises an amino acid sequence set forth in SEQ ID NO: 5.
6 . A nucleic acid, comprising a nucleic acid sequence set forth in SEQ ID NO: 6.
7 . A vector comprising a nucleic acid, wherein the nucleic acid comprises a nucleic acid sequence set forth in SEQ ID NO: 6.
8 . A pharmaceutical composition comprising a vector, wherein the vector comprises a nucleic acid, and wherein the nucleic acid comprises a nucleic acid sequence set forth in SEQ ID NO: 6.
9 . An immune cell comprising a nucleic acid, wherein the nucleic acid comprises a nucleic acid sequence set forth in SEQ ID NO: 6.
10 . A pharmaceutical composition comprising an immune cell, wherein the immune cell comprises a nucleic acid, and wherein the nucleic acid comprises a nucleic acid sequence set forth in SEQ ID NO: 6.
Assignments (5)
CHANGE OF NAME
Recorded Jan 19, 2024
From: CELLULAR BIOMEDICINE GROUP, INC.
To: ABELZETA INC.
Reel/Frame 066356/0108 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 15, 2022
From: CELLULAR BIOMEDICINE GROUP HK LTD.
To: CELLULAR BIOMEDICINE GROUP INC.
Reel/Frame 062105/0405 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 3, 2022
From: YAO, YIHONG; HUANG, JIAQI; ZHU, SHIGUI; ZHU, WEI; YAO, XIN; LI, ZHIYUAN; ZHANG, LI; ZHU, LIN; MA, ANYUN; WEI, YUTIAN; LI, YANFENG; WANG, QINGXIA; HE, JIAPING
To: CELLULAR BIOMEDICINE GROUP (SHANGHAI) LTD.; CELLULAR BIOMEDICINE GROUP (WUXI) LTD.
Reel/Frame 060099/0363 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 3, 2022
From: CELLULAR BIOMEDICINE GROUP (SHANGHAI) LTD.
To: CELLULAR BIOMEDICINE GROUP HK LIMITED
Reel/Frame 060099/0458 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 3, 2022
From: CELLULAR BIOMEDICINE GROUP (WUXI) LTD.
To: CELLULAR BIOMEDICINE GROUP HK LIMITED
Reel/Frame 060099/0542 →
Priority Claims (1)
CN 201710069569.7
· Feb 8, 2017
· national
Continuity (3)
Continuation
16484482
References Cited (269)
US 6074841A
· Gearing et al.
· 2000
[cited by applicant]
US 6410319B1
· Raubitschek et al.
· 2002
[cited by applicant]
US 7446179B2
· Jensen et al.
· 2008
[cited by applicant]
US 7446190B2
· Sadelain et al.
· 2008
[cited by applicant]
US 7462352B2
· Hansen et al.
· 2008
[cited by applicant]
US 8287864B2
· Goldenberg et al.
· 2012
[cited by applicant]
US 8329181B2
· Martin et al.
· 2012
[cited by applicant]
US 8389282B2
· Sadelain et al.
· 2013
[cited by applicant]
US 8399645B2
· Campana et al.
· 2013
[cited by applicant]
US 8529902B2
· Teeling et al.
· 2013
[cited by applicant]
US 8906682B2
· June et al.
· 2014
[cited by applicant]
US 8911993B2
· June et al.
· 2014
[cited by applicant]
US 8916381B1
· June et al.
· 2014
[cited by applicant]
US 8975071B1
· June et al.
· 2015
[cited by applicant]
US 9101584B2
· June et al.
· 2015
[cited by applicant]
US 9102760B2
· June et al.
· 2015
[cited by applicant]
US 9102761B2
· June et al.
· 2015
[cited by applicant]
US 9328156B2
· June et al.
· 2016
[cited by applicant]
US 9447194B2
· Jensen
· 2016
[cited by applicant]
US 9464140B2
· June et al.
· 2016
[cited by applicant]
US 9481728B2
· June et al.
· 2016
[cited by applicant]
US 9499629B2
· June et al.
· 2016
[cited by applicant]
US 9518123B2
· June et al.
· 2016
[cited by applicant]
US 9540445B2
· June et al.
· 2017
[cited by applicant]
US 9605049B2
· Campana et al.
· 2017
[cited by applicant]
US 9662354B2
· Hyde et al.
· 2017
[cited by applicant]
US 9834590B2
· Campana et al.
· 2017
[cited by applicant]
US 9856322B2
· Campana et al.
· 2018
[cited by applicant]
US 9919061B2
· McDonagh et al.
· 2018
[cited by applicant]
US 20090148447A1
· Ledbetter
· 2009
[cited by applicant]
US 20110091473A1
· Golab
· 2011
[cited by applicant]
US 20130004480A1
· Parren
· 2013
[cited by applicant]
US 20140093454A1
· Teeling et al.
· 2014
[cited by applicant]
US 20140154253A1
· Ng
· 2014
[cited by applicant]
US 20160333108A1
· Forman
· 2016
[cited by applicant]
US 20180044415A1
· Escarpe
· 2018
[cited by applicant]
US 20180118823A1
· Thompson
· 2018
[cited by applicant]
US 20180258391A1
· June et al.
· 2018
[cited by applicant]
US 20180319862A1
· Thompson et al.
· 2018
[cited by applicant]
US 20180355318A1
· Delaney et al.
· 2018
[cited by applicant]
US 20190112380A1
· Chaudhary
· 2019
[cited by applicant]
US 20200040096A1
· Forman et al.
· 2020
[cited by applicant]
US 20200093861A1
· Klein et al.
· 2020
[cited by applicant]
US 20200306375A1
· Lobb et al.
· 2020
[cited by applicant]
US 20210079111A1
· Zhang et al.
· 2021
[cited by applicant]
US 20210363245A1
· Kochenderfer et al.
· 2021
[cited by applicant]
US 20210388100A1
· Satpayev et al.
· 2021
[cited by applicant]
US 20230036065A1
· McCreedy, Jr. et al.
· 2023
[cited by applicant]
US 20230104705A1
· Yao et al.
· 2023
[cited by applicant]
US 20230212255A1
· Yao et al.
· 2023
[cited by applicant]
US 20230242613A1
· Yao et al.
· 2023
[cited by applicant]
US 20240034802A1
· Orentas et al.
· 2024
[cited by applicant]
US 20240115605A1
· Yao et al.
· 2024
[cited by applicant]
US 20240139243A1
· Yao et al.
· 2024
[cited by applicant]
US 20250144144A1
· Chen et al.
· 2025
[cited by applicant]
US 20250262243A1
· Yao
· 2025
[cited by examiner]
CN 101544694A
· 2009
[cited by applicant]
CN 106279434A
· 2017
[cited by applicant]
CN 107868791A
· 2018
[cited by applicant]
CN 107936120A
· 2018
[cited by applicant]
CN 108017717A
· 2018
[cited by applicant]
CN 108285486A
· 2018
[cited by applicant]
CN 108395482A
· 2018
[cited by applicant]
CN 108472346A
· 2018
[cited by applicant]
CN 108715616A
· 2018
[cited by applicant]
CN 109423495A
· 2019
[cited by applicant]
CN 109536455A
· 2019
[cited by applicant]
CN 109575143A
· 2019
[cited by applicant]
CN 110062768A
· 2019
[cited by applicant]
CN 110606893A
· 2019
[cited by applicant]
CN 110845623A
· 2020
[cited by applicant]
CN 112390891A
· 2021
[cited by applicant]
CN 112608387A
· 2021
[cited by applicant]
EP 3989986A1
· 2022
[cited by applicant]
JP 2015092865A
· 2015
[cited by applicant]
JP 2018508215A
· 2018
[cited by applicant]
WO 0023573A2
· 2000
[cited by applicant]
WO 2013123061A1
· 2013
[cited by applicant]
WO 2014012085A2
· 2014
[cited by applicant]
WO 2016014576A1
· 2016
[cited by applicant]
WO 2016097231A2
· 2016
[cited by applicant]
WO 2016100232A1
· 2016
[cited by applicant]
WO 2016126608A1
· 2016
[cited by applicant]
WO 2016139487A1
· 2016
[cited by applicant]
WO 2016166521A1
· 2016
[cited by applicant]
WO 2016179319A1
· 2016
[cited by applicant]
WO 2016201394A1
· 2016
[cited by applicant]
WO 2017025038A1
· 2017
[cited by applicant]
WO 2017149515A1
· 2017
[cited by applicant]
WO 2018067992A1
· 2018
[cited by applicant]
WO 2018068766A1
· 2018
[cited by applicant]
WO 2018121604A1
· 2018
[cited by applicant]
WO 2019028051A1
· 2019
[cited by applicant]
WO 2019075395A1
· 2019
[cited by applicant]
WO 2019126724A1
· 2019
[cited by applicant]
WO 2019128952A1
· 2019
[cited by applicant]
WO 2019129177A1
· 2019
[cited by applicant]
WO 2019154313A1
· 2019
[cited by applicant]
WO 2019206326A1
· 2019
[cited by applicant]
WO 2019210153A1
· 2019
[cited by applicant]
WO 2019223226A1
· 2019
[cited by applicant]
WO 2019232444A1
· 2019
[cited by applicant]
WO 2020010235A1
· 2020
[cited by applicant]
WO 2020033273A1
· 2020
[cited by applicant]
WO 2020061796A1
· 2020
[cited by applicant]
WO 2020072536A1
· 2020
[cited by applicant]
WO 2020151752A1
· 2020
[cited by applicant]
WO 2020210665A1
· 2020
[cited by applicant]
WO 2021188681A1
· 2021
[cited by applicant]
US 11,419,896 B2, 08/2022, Yao et al. (withdrawn)
[cited by applicant]
Rufener, Gregory A. et al., “Preserved Activity of CD20-Specific Chimeric Antigen Receptor-A Expressing T Cells in the Presence of Rituximab”, Cancer Immunology Research, 4(6), Jun. 2016, pp. 509-519.
[cited by applicant]
Wang, D. et al., “GenBank Accession No. AKH40187, Version AKH40187.1,” GenBank, Jul. 28, 2015.
[cited by applicant]
International Search Report/Written Opinion mailed May 9, 2018 for PCT/CN2018/075867, with translations.
[cited by applicant]
Lihua E. Budde et al., Combining a CD20 Chimeric Antigen Receptor and an Inducible Caspase 9 Suicide Switch to Improve the Efficacy and Safety of T Cell Adoptive Immunotherapy for Lymphoma, PLOS ONE, vol. 8, No. 12, 201…
[cited by applicant]
Ku Matthew et al., Tumour cell surface antigen targeted therapies in B-cell lymphomas: Beyond rituximab, Blood Reviews, vol. 31, No. 1, 2016, pp. 23-35.
[cited by applicant]
Andrew D. Fesnak et al., Engineered T Cells: The Promise and Challenges of Cancer Immunotherapy, Nature Reviews Cancer, vol. 16, No. 9, 2016, pp. 566-581 (in 2 parts).
[cited by applicant]
Extended European Search Report in EP18751050.8, dated Oct. 15, 2020.
[cited by applicant]
Jonnalagadda et al “ChimericAntigen Receptors With Mutated IgG4 Fc Spacer Avoid Fe Receptor Binding and Improve T Cell Persistence and Antitumor Efficacy.” Molecular Therapy 2015; vol. 23 No. 4, 757-768.
[cited by applicant]
Belovezhec T. N. Design and Comparative Analysis of CD20-Specific Chimeric Antigen Receptors. Proceedings of XIV International Conference of Students, Graduate Students and Young Scientists “Perspectives in Fundamental …
[cited by applicant]
Lopez-Atalaya et al. Development and Maintenance of the Brain's Immune Toolkit: Microglia and Non-Parenchymal Brain Macrophages. Dev Neurobiol. 2018; 78(6): 561-579.
[cited by applicant]
Riaz et al. Anti-CD19 and anti-CD20 CAR-modified T cells for B-cell malignancies: a systematic review and meta-analysis. Immunotherapy (2017) 9(12), 979-993.
[cited by applicant]
Nakagawa et al.
[cited by applicant]
Ramos et al. CAR-T Cell Therapy for Lymphoma. Annu. Rev. Med. 2016; 67: 165-183.
[cited by applicant]
Shetty et al. Liver sinusoidal endothelial cells—gatekeepers of hepatic immunity. Nat Rev Gastroenterol Hepatol. 2018; 15(9): 555-567.
[cited by applicant]
NCBI Accession AMZ04820, 2016, 1 page.
[cited by applicant]
NCBI Accession ANS59202, 2016, 1 page.
[cited by applicant]
Teeling et al. The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD20. J Immunol 2006; 177: 362-371.
[cited by applicant]
Korycka-Wolowiec et al. Ofatumumabfor treating chronic lymphocytic leukemia: a safety profile. Expert Opinion on Drug Safety 2015; 14(12): 1945-1959.
[cited by applicant]
Jabbour et al. Monoclonal antibodies in acute lymphoblastic leukemia. Blood 2015; 125(26): 4010-4016.
[cited by applicant]
Chuda et al. Ofatumumab: A Novel Anti-CD20Monoclonal Antibody for the Treatment of Chronic Lymphocytic Leukemia. Current Drug Therapy, 2012, 7, 281-289.
[cited by applicant]
Teeling et al. (2004) Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 104: 1793-1800.
[cited by applicant]
Lin TS (2010) Ofatumumab: a novel monoclonal ant / CD20antibody. Pharmacogenomics and Personalized Medicine 3: 51-59.
[cited by applicant]
Casan et al. (2018) Anti-CD20 monoclonal antibodies: reviewing a revolution. Human Vaccines & Immunotherapeutics 14(12): 2820-2841.
[cited by applicant]
Till et al. (2012) CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1 BB domains: pilot clinical trial results. Blood 119(17): 3940-3950.
[cited by applicant]
Hamdy et al. (2005) Sheep red blood cells armed with anti-CD20 single-chain variable fragments (scFvs) fused to a glycosylphosphatidylinositol (GPI) anchor: a strategy to target CD20-positive tumor cells. J. Immunol. Me…
[cited by applicant]
Gen Bank Accession AA022134.1 (2005), 2 pages.
[cited by applicant]
Wu et al. (2001) Multimerization of a chimeric anti-CD20single-chain Fv-Fc fusion protein is mediated through variable domain exchange. Protein Eng. 14: 1025-1033.
[cited by applicant]
Lulla et al. (2018) The Use of Chimeric Antigen Receptor T Cells in Patients with Non-Hodgkin Lymphoma, Clinical Advances in Hematology & Oncology, 16(5): 375-386.
[cited by applicant]
Hallek M. (2017) Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment. Am J Hematol. 92: 946-965.
[cited by applicant]
Cao et al. (2019) Efficiency and safety of autologous chimeric antigen receptor T-cells therapy used for patients with lymphoma. Medicine 98: 42(e17506), 8 pages.
[cited by applicant]
Till et al. (2008) Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-spetific T cells. Blood112(6): 2261-2271.
[cited by applicant]
Wang et al. (2014) Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells. Clinical Immunology 155: 160-175.
[cited by applicant]
Zhang et al. (2016) Treatment of CD20-directed Chimeric Antigen Receptor-modified T cells in patients with relapsed pr refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report. Signal Transduction and Tar…
[cited by applicant]
Jensen et al. (1998) CD20 is a molecular target for scFvFc:zeta receptor redirected T-cells: implications for cellular immunotherapy of CD20 malignancy. Biology of Blood and Marrow Transplant 4: 75-83.
[cited by applicant]
Chow et al. (2019) Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CART-cell therapy. Am. J. Hematol. 94(8): E209-E213.
[cited by applicant]
Patel, et al. (2020) “Expanding the Role of CAR-T Cell Therapy to Systemic Lupus Erythematosus”, EMJ Hematology, 8(1): 105-12. (Year: 2020).
[cited by applicant]
Non-final Office Action in U.S. Appl. No. 17/723,859, dated Aug. 4, 2022.
[cited by applicant]
Non-final Office Action in U.S. Appl. No. 17/750,855, dated Aug. 5, 2022.
[cited by applicant]
Buhler et al., Influence of structural variations on biological activity of anti-PSMA scFv and immunotoxins targeting prostate cancer. Anticancer Res. Sep. 2010;30(9):3373-9.
[cited by applicant]
Chavez et al., CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products. Ther Adv Hematol. Apr. 15, 2019;10:2040620719841581, 20 pages.
[cited by applicant]
Dondelinger et al., Understanding the Significance and Implications of Antibody Numbering and Antigen-Binding Surface/Residue Definition. Front Immunol. Oct. 16, 2018;9:2278, 15 pages.
[cited by applicant]
Du et al., Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20. Mol Immunol. Jul. 2009;46(11-12):2419-23.
[cited by applicant]
GenBank Accession No. AMZ04821.1, bi-specific chimeric antigen receptor 20-19 Short, partial [synthetic construct]. 1 page, Apr. 24, 2016.
[cited by applicant]
GenBank Accession No. KX000911, Synthetic construct bi-specific chimeric antigen receptor (EAAAK)3 20-19 Short gene, partial cds. 2 pages, Apr. 24, 2016.
[cited by applicant]
Ghafouri et al., CD19/CD20 bispecific chimeric antigen receptor (CAR) in naive/memory T-cells for the treatment of relapsed or refractory B-cell lymphomas. Jul. 1, 2021;81(13):Abstract CT007.
[cited by applicant]
Kim et al., Improving the productivity of single-chain Fv antibody against c-Met by rearranging the order of its variable domains. J Microbiol Biotechnol. Jun. 2008;18(6):1186-90.
[cited by applicant]
Kipriyanov et al., Effect of domain order on the activity of bacterially produced bispecific single-chain Fv antibodies. J Mol Biol. Jun. 27, 2003;330(1):99-111.
[cited by applicant]
Kunik et al., Structural consensus among antibodies defines the antigen binding site. PLoS Comput Biol. 2012;8(2): e1002388.
[cited by applicant]
Kussie et al., A single engineered amino acid substitution changes antibody fine specificity. J Immunol. Jan. 1, 1994;152(1):146-52.
[cited by applicant]
Liang et al., Safety and efficacy of a novel anti-CD20/CD19 bi-specific CAR T-cell therapy (C-CAR039) in relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL). Journal of Clinical Oncology. May 20, 2021;39(15…
[cited by applicant]
Liu et al., Fine mapping of the antigen-antibody interaction of scFv215, a recombinant antibody inhibiting RNA polymerase II from
[cited by applicant]
Makita et al., Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma. Cancer Sci. Jun. 2017;108(6):1109-1118.
[cited by applicant]
Martyniszyn et al., CD20-CD19 Bispecific CAR T Cells for the Treatment of B-Cell Malignancies. Hum Gene Ther. Dec. 2017;28(12):1147-1157.
[cited by applicant]
Panka et al., Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies. Proc Natl Acad Sci U S A. May 1988;85(9):3080-4.
[cited by applicant]
Rudikoff et al., Single amino acid substitution altering antigen-binding specificity. Proc Natl Acad Sci U S A. Mar. 1982;79(6):1979-83.
[cited by applicant]
Schneider et al., A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines. Journal for Immuno Therapy of Cancer. 2017;5:42, 17 pages.
[cited by applicant]
Sela-Culang et al., The structural basis of antibody-antigen recognition. Front Immunol. Oct. 8, 2013;4:302.
[cited by applicant]
Shah et al., Bispecific anti-CD20, anti-CD19 Car T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nat Med. Oct. 2020;26(10):1569-1575.
[cited by applicant]
Tong et al., Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma. Blood. Oct. 1, 2020;136(14):1632-1644.
[cited by applicant]
Wark et al., Latest technologies for the enhancement of antibody affinity. Adv Drug Deliv Rev. Aug. 7, 2006;58(5-6):657-70.
[cited by applicant]
Watanabe et al., Target antigen density governs the efficacy of anti-CD20-CD28-CD3 ? chimeric antigen receptor- modified effector CD8+ T cells. J Immunol. Feb. 1, 2015;194(3):911-20.
[cited by applicant]
Wong et al., Structural requirements for a specificity switch and for maintenance of affinity using mutational analysis of a phage-displayed anti-arsonate antibody of Fab heavy chain first complementarity-determining re…
[cited by applicant]
Zah et al., Addendum: T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells. Cancer Immunol Res. Jul. 2016;4(7):639-41.
[cited by applicant]
Zah et al., T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells. Cancer Immunol Res. Jun. 2016;4(6):498-508.
[cited by applicant]
Zhou et al., The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor-T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysis. BMC Cancer. Sep. 26, 2018;18(1):929, 13 pages.
[cited by applicant]
Zhu et al., Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center. Cytotherapy. Mar. 2018;20(3):394-406.
[cited by applicant]
International Search Report and Written Opinion for Application No. PCT/CN2020/109645, dated Dec. 16, 2020, 15 pages.
[cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2021/022779, dated Aug. 9, 2021, 16 pages.
[cited by applicant]
International Search Report and Written Opinion of PCT/US22/13875, mailed Jul. 8, 2022.
[cited by applicant]
U.S. Appl. No. 17/475,766, filed Sep. 15, 2021, U.S. Pat. No. 11,439,665, Issued.
[cited by applicant]
U.S. Appl. No. 17/721,647, filed Apr. 15, 2022, 2022-0249568, Published.
[cited by applicant]
U.S. Appl. No. 17/750,658, filed May 23, 2022, U.S. Pat. No. 11,633,430, Issued.
[cited by applicant]
U.S. Appl. No. 17/911,502, filed Sep. 14, 2022, 2023-0104705, Published.
[cited by applicant]
U.S. Appl. No. 17/911,524, filed Sep. 14, 2022, 2023-0212255, Published.
[cited by applicant]
U.S. Appl. No. 18/183,681, filed Mar. 14, 2023, 2024-0139243, Published.
[cited by applicant]
U.S. Appl. No. 16/877,069, filed May 18, 2020, U.S. Pat. No. 11,207,349, Issued.
[cited by applicant]
U.S. Appl. No. 16/484,482, filed Aug. 8, 2019, U.S. Pat. No. 11,066,457, Issued.
[cited by applicant]
U.S. Appl. No. 17/352,915, filed Jun. 21, 2021, U.S. Pat. No. 11,472,858, Issued.
[cited by applicant]
U.S. Appl. No. 17/723,859, filed Apr. 19, 2022, U.S. Pat. No. 11,618,778, Issued.
[cited by applicant]
U.S. Appl. No. 17/750,855, filed May 23, 2022, U.S. Pat. No. 11,608,369, Issued.
[cited by applicant]
U.S. Appl. No. 18/173,187, filed Feb. 23, 2023, 2023-0242613, Published.
[cited by applicant]
U.S. Appl. No. 18/263,050, filed Jul. 26, 2023, 2024-0115605, Published.
[cited by applicant]
ClinicalTrials.gov, NCT03019055, Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell. 15 pages, Jul. 27, 2023.
[cited by applicant]
Li et al., Clinical Responses and Pharmacokinetics of fully human BCMA Targeting CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma. 17th International Myeloma Workshop. pp. e23-e24, Abstract 0AB-033, Sep. 12-15…
[cited by applicant]
Raje et al., Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. N Engl J Med. May 2, 2019;380(18):1726-1737.
[cited by applicant]
Jayaraman et al., CAR-T design: Elements and their synergistic function. EBioMedicine. Aug. 2020;58:102931, 12 pages.
[cited by applicant]
Dudek et al., Mitochondrial protein import: common principles and physiological networks. Biochim Biophys Acta. Feb. 2013;1833(2):274-85.
[cited by applicant]
Edwards et al., The remarkable flexibility of the human antibody repertoire; isolation of over one thousand different antibodies to a single protein, BLyS. J Mol Biol. Nov. 14, 2003;334(1):103-18.
[cited by applicant]
Goel et al., Plasticity within the antigen-combining site may manifest as molecular mimicry in the humoral immune response. J Immunol. Dec. 15, 2004;173(12):7358-67.
[cited by applicant]
Kosugi et al., Six classes of nuclear localization signals specific to different binding grooves of importin alpha. J Biol Chem. Jan. 2, 2009;284(1):478-485.
[cited by applicant]
Sadelain et al., The basic principles of chimeric antigen receptor design. Cancer Discov. Apr. 2013;3(4):388-98.
[cited by applicant]